Major Investor Group, Including Director, Boosts Stake in Surrozen with $6M in Recent Stock Purchases
SRZN has more than doubled off its 52-week low of $5.9.
Summary
A major institutional investor group, including a board director, reported approximately $6.0 million in recent stock purchases, significantly increasing their stake in Surrozen, Inc.
Key Events · Ownership and Investor Activity · SRZN
-
Significant Insider Buying
The Column Group, a major institutional investor, reported approximately $6.0 million in stock purchases between November 2025 and January 2026.
-
Increased Beneficial Ownership
The purchases, made by affiliated funds, represent a substantial increase in their stake, now totaling 35.1% of the company's common stock for individuals Tim Kutzkey (a director) and Peter Svennilson.
-
Director Confidence
Tim Kutzkey, a member of Surrozen's board of directors, is part of the reporting group, signaling strong insider confidence.
-
Material Investment
The aggregated purchases amount to approximately 3.5% of Surrozen's market capitalization, indicating a material commitment from a key investor.
Analysis · SRZN · Life Sciences
The Column Group, a significant institutional investor in Surrozen, Inc., along with its managing partners including board member Tim Kutzkey, has substantially increased its beneficial ownership through a series of stock purchases totaling approximately $6.0 million. These purchases, made between November 2025 and January 2026, represent a significant vote of confidence from a key long-term investor and director, indicating a strong belief in the company's future prospects. The aggregated purchases amount to approximately 3.5% of the company's current market capitalization, signaling a material increase in their commitment.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRZN was trading at $20.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.4M. The 52-week trading range was $5.90 to $24.94. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.